LP 605 Pill — YELLOW;WHITE CAPSULE, 18mm — Temozolomide

No photo available
View full Temozolomide profile
ImprintLP / 605
ColourYELLOW;WHITE
ShapeCAPSULE
Size18
StrengthTEMOZOLOMIDE 20 mg
Dosage formCapsule
ManufacturerRising Pharmaceuticals, Inc.
NDC64980-334
Schedule—
Availability—
IngredientsTEMOZOLOMIDE[TEMOZOLOMIDE]

What does this imprint mean?

The imprint "LP 605" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Temozolomide

Uses and warnings

BOXED WARNING: Myelosuppression - "Myelosuppression, including pancytopenia, leukopenia...and anemia, some with fatal outcomes, have occurred," with approximately 10% of patients requiring hospitalization or transfusion; blood counts must be monitored, with nadirs typically around day 26-28. Hepatotoxicity - "Fatal and severe hepatotoxicity have been reported" and liver function should be checked at baseline, mid-cycle, and after each cycle. Secondary malignancies, including myelodysplastic syndrome and secondary leukemias, have been observed. Contraindicated in patients with prior serious hypersensitivity to temozolomide or dacarbazine (shared metabolite). Also warns of Pneumocystis pneumonia risk, especially with concurrent steroid use, and embryo-fetal toxicity.

Indicated for adults with "newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment," and for "adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma" as well as "treatment of adults with refractory anaplastic astrocytoma."

Read the full drug profile →

How to identify this pill

Similar-looking pills

Other pills of Temozolomide

Official references

Source: FDA Structured Product Label via NLM Pillbox archive (retired 2021); source file 1c22f9d0-ae27-4e69-8b33-e634071128e8.xml